MARKET WIREFierce Biotech • 15h ago
Bolt makes inflammation play with Prana reverse merger, $120M financingFierce Biotech report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
Why BOLT Stock surged +3.62% Today — RQD Quant Desk Flash
$6.59 +3.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.62
Bolt Biotherapeutics Inc. (BOLT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $12.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BOLT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $6.59 (+3.62% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #550 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BOLT compare to JAGX and HIND in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and HIND (Vyome Holdings Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BOLT?
▼
Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.62 (+0.46%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BOLT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY BOLT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (35% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)
FRED Regime × Technicals: 75% of 52W Range • RSI-14 at 72.4 (OVERBOUGHT (>70))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.28+0.7% Next Q
29
Q2 (-2Q)Grade E$4.31+47.8% Next Q
32
Q3 (-1Q)Grade E$6.37+3.5% Next Q
34
CurrentGrade D-$6.59-8.1% Hist 90D α
37
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BOLT Turnaround Squeeze
While BOLT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($6.92) forces dealer call-delta covering toward $8.17.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BOLT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BOLT Stock surged +3.62% Today — RQD Quant Desk Flash
Bolt Biotherapeutics Inc. (BOLT) surged +3.62% to $6.59, trading at 75% of its 52-week range ($3.1 – $7.78). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 75% of its 52-week range ($3.1 – $7.78) with RSI-14 at 72.4 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BOLT Headlines & Catalysts
MARKET WIREYahoo Finance • 18h ago
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory IndicationsYahoo Finance report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvestorideas.com • 21h ago
Biotech Stock Bolt Biotherapeutics (Nasdaq: BOLT) Soars on Acquisition NewsInvestorideas.com report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Pharma Letter • 1d ago
Bolt Biotherapeutics acquires Prana TherapiesThe Pharma Letter report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
Bolt Biotherapeutics, Inc. announced that it expects to receive $119.999995 million in funding from a group of investorsmarketscreener.com report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREcitybiz • 1d ago
Bolt Biotherapeutics Acquires Prana Therapies, Secures $120 Million Financing to Advance Clinical Pipelinecitybiz report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Bolt Biotherapeutics Completes Prana Merger Alongside $120 Million FinancingTradingView report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 5d ago
Lilly shuffles business structure; Novartis writes off part of Avidity dealLilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
RISK WATCHChartMill • 7d ago
Unusual Volume in Small-Cap US Stocks: Mixed Session of Gains and Sharp LossesUnusual volume in US small-cap stocks: RBNE, SHFS, AARD, XXII and others traded well above 50-day averages, with sharp losses and double-digit gains.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLT)
- ✓Walkthrough of BOLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BOLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.24%📐 HORIZONTAL RANGE
2026-11-03O $6.36H $6.59L $6.36C $6.59VOL 249.9K
RES: $7.92SUP: $3.06SMA50: $4.25SMA200: $4.51
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BOLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +0.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BOLT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BOLT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BOLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLT)
Health Care Rank #550 of 1016
⚔️ JAGX vs BOLT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BOLT vs. JAGX, HIND, BFRI, BIVI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bolt Biotherapeutics Inc. (BOLT) ranks #550 by composite RQD confidence (37/100, grade D-) and #869 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, BOLT leads on earnings valuation at N/A trailing P/E, while BOLT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BOLT currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BOLT
ACTIVE
Bolt Biotherapeutics Inc. | D- | 37/100 | — | — | -35.0% | +3.62% | $12.7M | Benchmark Subject |
| JAGX Jaguar Health Inc. | E | 28/100 | — | 67.2% | -35.0% | -20.59% | $12.6M | /jagx-vs-bolt → |
| HIND Vyome Holdings Inc. | E | 29/100 | — | 68.4% | -35.0% | +2.86% | $12.6M | /hind-vs-bolt → |
| BFRI Biofrontera Inc. | E | 26/100 | — | — | -35.0% | -6.29% | $13.0M | /bfri-vs-bolt → |
| BIVI BioVie Inc. (Class A) | E | 32/100 | — | — | -35.0% | +3.62% | $12.4M | /bivi-vs-bolt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001641281In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bolt Biotherapeutics Inc. (BOLT) reported GAAP revenue of $7.7M (+0.1% vs. FY2024 revenue of $7.7M , and -2.3% cumulative change since FY2023) , GAAP net income of -$33.4M, operating cash flow of -$39.9M, and free cash flow of -$39.9M (+34.9% YoY). On the balance sheet, BOLT closed FY2025 with $56.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.7M | -$33.4M | -$39.9M | -$39.9M | $56.7M | — |
| FY2024 (FY) | 2024-12-31 | $7.7M | -$63.1M | -$61.3M | -$61.3M | $99.6M | — |
| FY2023 (FY) | 2023-12-31 | $7.9M | -$69.2M | -$69.5M | -$69.5M | — | — |
3. BOLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $6.59 (+3.62% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #550 in composite RQD confidence.
How does BOLT compare to JAGX and HIND in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and HIND (Vyome Holdings Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BOLT?
Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BOLT trading relative to its 50-day, 200-day, and 52-week technical levels?
BOLT last traded at $6.59 (+3.62% on volume of 249,919 shares), positioning the stock +55.06% above its 50-day simple moving average ($4.25) and +46.12% above its 200-day simple moving average ($4.51). Across its 52-week range of $3.10 to $7.78, BOLT sits at the 74.6% percentile with a 14-day RSI of 72.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.77 to $7.41).
BOLT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BOLT stock moving today?
Why BOLT Stock surged +3.62% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BOLT — Bolt Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:17Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BOLT scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 4 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For an investor, this indicates the business is not currently generating returns on capital or free cash flow, so value must rest on future outcomes rather than present earnings power.
- Whale 13F Flow: 14 / 20. Described as institutional accumulation and options positioning. This is the strongest pillar, suggesting some institutional interest, though the rating does not disclose the magnitude or direction of specific holdings.
- Insider Conviction: 3 / 20. Based on SEC Form 4 and Congressional PTR cluster flow. A low score here means insider activity provides little supporting conviction signal.
- Macro Regime Fit: 9 / 20. Beta of 1.0 with sector sensitivity noted. The stock's market sensitivity is neutral, but the score reflects limited alignment with the prevailing regime.
- Forensic Balance Sheet: 8 / 20. Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5. These point to elevated financial fragility and weak fundamental quality signals.
Taken together, the rating frames BOLT as a speculative, cash-consuming company whose equity value is highly dependent on near-term financing and clinical or strategic outcomes. The score does not imply a precise price target; it reflects a weak composite profile across fundamentals, balance sheet, and insider signals, partially offset by institutional interest.
Business
Bolt Biotherapeutics Inc. (BOLT) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is a publicly traded biotechnology business. Source data does not specify its products, customers, or revenue model. Per the SEC financials, reported revenue was $7.7M for FY 2025 and $7.7M for FY 2024. Per recent news, the company announced an acquisition of Prana Therapies alongside a $120 Million concurrent private placement to advance PRA-216 in inflammatory indications.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $7.7M | $-36.1M | $-33.4M | N/A | $-39.9M | $11.7M | N/A |
| FY 2024 | $7.7M | $-73.0M | $-63.1M | N/A | $-61.3M | $7.2M | N/A |
| FY 2023 | $7.9M | $-76.2M | $-69.2M | N/A | $-69.5M | N/A | N/A |
Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported operating losses and negative free cash flow persisted across the three periods shown. Reported cash rose to $11.7M in FY 2025 from $7.2M in FY 2024, while debt is not available in source data.
Recent Catalysts & News Wire Analysis
- Primary catalyst (per the news wire): Multiple outlets, including Fierce Biotech, Yahoo Finance, The Pharma Letter, marketscreener.com, and citybiz, report the Prana Therapies acquisition and a $120 Million financing. One marketscreener.com item references expected funding of $119.999995 million.
- Market reaction: An Investorideas.com item reports the stock "soars on acquisition news," and one item is tagged as a green-light catalyst. Current price of 6.36 reflects a -3.34% change per the market data.
- Risk watch items: Most items are tagged as yellow-light market wire, signaling mixed or unconfirmed signal strength. The financing is a concurrent private placement, which may imply dilution; source data does not quantify share issuance.
- Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that the acquisition of Prana Therapies and the PRA-216 program are the only identifiable ripple pathways in the news, and their operational interdependencies are not specified in source data.
Open Questions
- What are the specific terms, share count, and dilution impact of the $120 Million concurrent private placement?
- What is the status and stage of PRA-216, and what clinical or commercial milestones are associated with the Prana acquisition?
- What is BOLT's debt position, given debt is listed as N/A across all periods?
- Why does reported revenue hold flat at $7.7M across FY 2025 and FY 2024, and what drives it?
- What is the source and composition of the 14/20 institutional 13F flow, including the identity and size of major holders?
BOLT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bolt Biotherapeutics Inc. (BOLT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Fierce Biotech • 15h ago
Bolt makes inflammation play with Prana reverse merger, $120M financing Fierce Biotech report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 18h ago
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications Yahoo Finance report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investorideas.com • 21h ago
Biotech Stock Bolt Biotherapeutics (Nasdaq: BOLT) Soars on Acquisition News Investorideas.com report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Pharma Letter • 1d ago
Bolt Biotherapeutics acquires Prana Therapies The Pharma Letter report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
Bolt Biotherapeutics, Inc. announced that it expects to receive $119.999995 million in funding from a group of investors marketscreener.com report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE citybiz • 1d ago
Bolt Biotherapeutics Acquires Prana Therapies, Secures $120 Million Financing to Advance Clinical Pipeline citybiz report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session Benzinga report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Bolt Biotherapeutics Completes Prana Merger Alongside $120 Million Financing TradingView report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BOLT Bull vs. Bear Conversation Board — What's Your Call at $6.59?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BOLT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $5.60 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BOLT (D- • RQD 38/100) a Buy at $6.36?
Welcome to the BOLT (Bolt Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.77 (-25.0%)
Spot @ $6.36 Pump the brakes on BOLT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BOLT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Bolt Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $7.82 (+23.0%)
Spot @ $6.36 BOLT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BOLT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.36 (52-wk range $3.10 - $7.78), any beat on forward guidance forces shorts and underweight funds to chase.